Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:APRI Apricus Biosciences (APRI) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsTrends About Apricus Biosciences Stock (NASDAQ:APRI) 30 days 90 days 365 days Advanced Chart Ad Traders Agency5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here.Click here to pay just $5 for a full year of Stealth Trades Get Apricus Biosciences alerts:Sign Up Key Stats Today's Range$0.54▼$0.7550-Day Range N/A52-Week Range$0.18▼$3.34Volume47,441 shsAverage Volume558,386 shsMarket Capitalization$15.21 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewSeelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system disorders. The firm's portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior in Major Depressive Disorder �or Post-Traumatic Stress Disorder, �amyotrophic lateral sclerosis, Sanfilippo syndrome, Parkinson's disease, other psychiatric and movement disorders plus orphan diseases. The company was founded by Raj Mehra in 2016 and is headquartered in New York, NY.Read More… 5 Stocks that could triple in a week (Ad)Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here.Click here to pay just $5 for a full year of Stealth Trades Receive APRI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Apricus Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address APRI Stock News HeadlinesEnlyte Launches Apricus Physical Medicine, Offering End-to-End Specialty Service Solution for IndustryOctober 10, 2024 | tmcnet.comApricus Generation Acquires Solar and Storage Developer Nexus RenewablesMay 29, 2024 | tmcnet.comWhy buying gold might be a mistakeSomething strange just happened with gold. With the recent Fed rate cut… My charts are showing a breakout signal I haven't seen in years. But for now, I'm not rushing to buy gold. In fact, I'm telling everyone I know to hold off. Because I believe there’s a far better way to play this upcoming surge. It's a method that could turn a 1% gold price change into gains like 59%, 118%, or even 228%. And it doesn't involve buying a single ounce of physical gold or even buying any regular gold stock. I've been trading gold for nearly 20 years now and this is my #1 recommended approach for trading gold right now. Most traders miss them completely… But for those who know how to spot them, it takes their trades to a whole new level.November 17, 2024 | DTI (Ad)Lundquist Institute Start-Up Vitalex Biosciences Awarded Grant from NIAID/NIHMay 16, 2023 | finance.yahoo.comErectile Dysfunction Market Analysis and Growth Foresights till 2031May 16, 2023 | marketwatch.comErectile Dysfunction Drugs Market Market Projection and Growth Drivers 2023-2028April 29, 2023 | marketwatch.comErectile Dysfunction Drugs Market 2023-2028 Recent Study by Trend and Growth AnalysisMarch 11, 2023 | marketwatch.comErectile Dysfunction Medicine Market : Key Player, Competition Weakness and Strengths from 2023 to 2028January 10, 2023 | marketwatch.comSee More Headlines APRI Stock Analysis - Frequently Asked Questions How were Apricus Biosciences' earnings last quarter? Apricus Biosciences, Inc. (NASDAQ:APRI) announced its earnings results on Wednesday, October, 31st. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.02. What other stocks do shareholders of Apricus Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Apricus Biosciences investors own include Scotts Miracle-Gro (SMG), Pfizer (PFE), Just Eat Takeaway.com (GRUB), Boston Beer (SAM), Amicus Therapeutics (FOLD), Palatin Technologies (PTN) and Synergy Pharmaceuticals (SGYP). Company Calendar Last Earnings10/31/2018Today11/17/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:APRI CUSIPN/A CIK1017491 Webwww.apricusbio.com Phone(646) 293-2100FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$320,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-216.45% Return on Assets-153.13% Debt Debt-to-Equity RatioN/A Current Ratio3.86 Quick Ratio3.86 Sales & Book Value Annual Sales$5.76 million Price / Sales2.64 Cash FlowN/A Price / Cash FlowN/A Book Value$0.29 per share Price / Book1.86Miscellaneous Outstanding Shares28,170,000Free FloatN/AMarket Cap$15.21 million OptionableNot Optionable Beta1.20 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report This page (NASDAQ:APRI) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apricus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apricus Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
